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Purpose: To investigate the effect of pretreatment with intravenous nicorandil on 
the incidence of contrast-induced nephropathy (CIN) in patients with renal dys-
function undergoing coronary angiography. Materials and Methods: This ran-
domized controlled multicenter study enrolled a total of 166 patients (nicorandil 
n=81; control n=85) with an estimated glomerular filtration rate <60 mL/min. 
Nicorandil 12 mg dissolved in 100 mL of 0.9% saline was administered intrave-
nously for 30 minutes just prior to coronary angiography in the nicorandil group. 
The same volume of only saline was given to the control group. The primary end-
point was the incidence of CIN, defined as >0.5 mg/dL increase or >25% rise in 
serum creatinine (SCr) concentration within 48 hours of contrast exposure com-
pared to baseline. Results: The final analysis included 149 patients (nicorandil 
n=73; control n=76). The baseline characteristics and the total volume of the used 
contrast (Iodixanol, 125.6±69.1 mL vs. 126.9±74.6 mL, p=0.916) were similar be-
tween the two groups. The incidence of CIN also did not differ between the nicor-
andil and control groups (6.8% vs. 6.6%, p=0.794). There was no difference be-
tween the two groups in the relative change in SCr from baseline to peak level 
within 48 hours after coronary angiography (-1.58±24.07% vs. 0.96±17.49%, 
p=0.464), although the nicorandil group showed less absolute change in SCr than 
the control group (-0.01±0.43 mg/mL vs. 0.02±0.31 mg/mL, p=0.005). Conclu-
sion: Prophylactic intravenous infusion of nicorandil did not decrease the inci-
dence of CIN in patients with renal dysfunction undergoing coronary angiography.
Key Words:   Contrast media, acute kidney injury, coronary artery disease
INTRODUCTION
With the widespread use of computed tomography and angiography as diagnostic 
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cedure. 
This study was conducted according to the principles of 
the revised Declaration of Helsinki and good clinical prac-
tice guidelines and was approved by the local Institutional 
Review Board of the participating hospitals. All patients 
gave written informed consent prior to study entry. The trial 
was registered with http://www.clinicaltrials.gov (trial iden-
tifier: NCT01103336).
Study protocol
The present study was designed as an investigator-initiated, 
prospective, randomized, open-label, multicenter trial. Pa-
tients were randomized in a 1 : 1 ratio either to the nicor-
andil or to the control group. Randomization was stratified 
for the participating centers and the severity of the renal 
dysfunction (eGFR ≤40 or >40 mL/min). In the nicorandil 
group, nicorandil (Sigmart for injection, Choongwae Phar-
ma, Seoul, Korea) 12 mg nicorandil was diluted in 100 mL 
of 0.9% saline and administered intravenously over a 
30-minute period just prior to coronary angiography. In the 
control group, 100 mL of 0.9% saline was given by the 
same method. In all enrolled patients, an intravenous infu-
sion of 0.45% saline at a rate of 1 mL/kg/hr (0.5 mL/kg/hr 
for patients with LVEF <40%) was administered at least 8 
hours before and after an elective coronary procedure. Elec-
tive coronary procedures were performed according to stan-
dard technique by a radial or femoral approach. Iodixanol 
(Visipaque, GE Healthcare Korea, Seoul, Korea), an iso-os-
molar, non-ionic, dimeric contrast medium, was used for all 
patients. 
Blood samples were collected at baseline and on days 1 
and 2 after the procedure for the measurement of serum Cr 
and cystatin C levels. Laboratory personnel in a central core 
laboratory (Seoul Clinical Laboratory, Seoul, Korea) that 
were fully blinded to the clinical data performed the mea-
surements. The primary endpoint was the incidence of CIN, 
defined as >0.5 mg/dL increase or >25% rise in SCr concen-
tration within 48 hours of contrast exposure compared to 
baseline. Additional endpoints were maximal increase in se-
rum Cr and cystatin C levels within 48 hours after the proce-
dure. Major adverse events including death, myocardial in-
farction, stroke, renal failure requiring dialysis, and acute 
pulmonary edema confirmed by chest X-ray films were also 
recorded.
Statistical analysis
The calculation of the sample size was based on a two sam-
tools for various diseases, the prevalence of contrast-in-
duced nephropathy (CIN) is increasing, and CIN is a com-
mon cause of hospital-acquired acute renal failure.1-3 Risk 
factors for CIN include chronic kidney disease, diabetes mel-
litus, advanced age, congestive heart failure, nephrotoxic 
drug use, hypovolemia, and excessive contrast media vol-
ume.4,5 The incidence of CIN is less than 5% in patients with-
out risk factors but can increase to 50% among patients with 
multiple risk factors.4,5 Although the underlying pathomecha-
nism for CIN is not fully understood, the reduction in renal 
perfusion caused directly from the effect of contrast media on 
the kidney plays an important role in the development of 
CIN.6,7 Nicorandil is an anti-anginal medication that has the 
dual properties of a KATP channel agonist and a nitric oxide 
(NO) donor.8 A recent study showed that activation of the 
KATP channel reduced renal injury due to ischemia and reper-
fusion by preventing accumulation of reactive oxygen radi-
cals.9 These data suggest that nicorandil may protect the kid-
ney from ischemic injury associated with the use of contrast 
media by decreasing calcium inflow to the tubular cells, in-
hibiting the accumulation of reactive oxygen species (ROS), 
suppressing synthesis of endothelin-1, and inducing NO pro-
duction. The purpose of the present study is to evaluate the 
effect of pretreatment with intravenous nicorandil on the inci-
dence of CIN in patients with renal dysfunction undergoing 
coronary angiography.
MATERIALS AND METHODS
　　　
Study population
Patients admitted with renal dysfunction [i.e., estimated 
glomerular filtration rate (eGFR) ≤60 mL/min by Cock-
croft-Gault formula and serum creatinine (SCr) ≥1.1 mg/
dL] scheduled to undergo coronary angiography on the 
next day were screened. The exclusion criteria were age 
<18 years, acute myocardial infarction requiring primary or 
rescue coronary intervention, allergy to contrast dye or 
nicorandil, previous exposure to nicorandil or contrast me-
dium within the preceding 7 days, pregnancy, left ventricu-
lar ejection fraction (LVEF) <30% by echocardiogram or 
evident by pulmonary edema, acute renal failure, renal fail-
ure requiring dialysis, a single functioning kidney, history 
of kidney transplantation, life expectancy <6 months, or the 
use of nonsteroidal anti-inflammatory drugs except for low 
dose aspirin, dopamine, mannitol, N-acetylcysteine, ascor-
bic acid, or sodium bicarbonate within 48 hours of the pro-
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RESULTS
 
Baseline characteristics
A total of 173 patients were enrolled in this study and were 
randomized to either the nicorandil group (n=85) or the con-
trol group (n=88). Two patients from each group withdrew 
consent for study participation after enrollment. An addi-
tional 20 patients, 10 from each group, were excluded from 
the analysis because of incomplete laboratory evaluations. 
Consequently, 73 patients in the nicorandil group and 76 pa-
tients in the control group remained for statistical analysis. 
Clinical characteristics of the patients are summarized in Ta-
ble 1. No significant differences were identified between the 
two patient groups regarding age, gender, weight, body 
mass index, diabetes mellitus, hypertension, hypercholester-
olemia, current smoking, acute coronary syndrome, acute 
myocardial infarction, multi-vessel disease, eGFR, Mehran 
ple and two-sided inequality test. The incidence of CIN was 
approximated at 15% in the control group based on previ-
ous studies.4,5,10 Pretreatment with nicorandil was hypothe-
sized to reduce this incidence to 2%. Based on an alpha level 
of 0.05 and statistical power of 80%, 73 patients were re-
quired for each group. Continuous variables were expressed 
as mean±standard deviation, and categorical variables were 
described as a number (percentage). Categorical variables 
were compared using the chi-square test or Fisher’s exact 
test, as appropriate. Student’s t-tests were used to compare 
normally and non-normally distributed continuous variables. 
Statistical significance was considered if the p-value was 
<0.05. The impact of the pretreatment of nicorandil on the 
incidence of CIN was evaluated in a logistic regression anal-
ysis after adjustment of all variables associated with CIN in 
univariate analysis with a p-value <0.2. All statistical analy-
ses were conducted using IBM PASW Statistics 18.0 (IBM 
Corporation, New York, NY, USA).
Table 1. Clinical Characteristics of the Study Population
Nicorandil (n=73) Control (n=76) p value
Age, yrs 70.8±9.6   69.1±10.3 0.291
Male (%)    53 (72.6) 51 (67.1) 0.581
Weight, kg   63.8±11.6   65.4±11.1 0.383
BMI, kg/m2 24.1±3.2 24.8±3.7 0.229
Diabetes mellitus (%)    30 (41.1) 42 (55.3) 0.117
Hypertension (%)    57 (78.1) 61 (80.3) 0.900
Hypercholesterolemia (%)    21 (28.8) 28 (36.8) 0.382
Current smoker (%)    17 (23.3) 18 (23.7) 0.892
Acute coronary syndrome (%)    24 (32.9) 21 (27.6) 0.604
AMI (%)    5 (6.8) 5 (6.6) 0.794
Multi-vessel disease (%)    35 (47.9) 28 (36.8) 0.228
LVEF ≤45% (%)    11 (15.1) 5 (6.6) 0.159
Baseline eGFR, mL/min   37.5±13.4   40.1±13.9 0.248
eGFR <40 mL/min (%)    37 (50.7) 40 (52.6) 0.941
Mehran score (%) 0.571
    0-5    20 (27.4) 21 (27.6)
    5-10    35 (47.9) 36 (47.4)
    11-16    18 (24.7) 17 (22.4)
    >16 0 (0) 2 (2.6)
    Mean   7.8±3.5   7.9±3.8 0.974
Previous medications (%)*
    ACEI or ARB    47 (64.4) 43 (56.6) 0.420
    β-blocker    42 (57.5) 35 (46.1) 0.216
    Calcium-channel blocker    34 (46.6) 36 (47.4) 0.919
    Nitrate    37 (50.7) 43 (56.6) 0.485
    Statin    37 (50.7) 43 (56.6) 0.640
BMI, body mass index; AMI, acute myocardial infarction; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; ACEI, angioten-
sin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker. 
*Medications prior to coronary angiography.
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24 and 48 hours after the procedure did not show any sig-
nificant difference between the two groups. The primary 
endpoint (incidence of CIN) was also similar between the 
nicorandil and control groups (6.8% vs. 6.6%, p=0.794) 
(Fig. 1). The change in absolute serum Cr level within 48 
hours after the exposure to contrast media showed signifi-
cantly less change in the nicorandil group compared to the 
control group, respectively (-0.01±0.43 mg/dL vs. 0.02± 
0.31 mg/dL, p=0.005). However, the relative changes in se-
rum Cr from baseline to maximal Cr level within 48 hours 
were not significantly different between the nicorandil and 
control groups (-1.58±24.07% vs. 0.96±17.49%, p=0.464). 
The absolute (0.08±0.25 mg/L vs. 0.09±0.15 mg/L, p=0.867) 
and relative changes in the serum cystatin C levels (5.57± 
score, and previous medications. However, the nicorandil 
group had a trend toward a higher frequency of LVEF ≤45% 
compared to the control group (15.1% vs. 6.6%, p=0.159). 
Contrast-induced nephropathy (CIN)
The procedural and biochemical characteristics are present-
ed in Table 2. The frequency of percutaneous coronary in-
tervention (PCI) (41.1% vs. 36.8%, p=0.716) and the vol-
ume of contrast media (125.6±69.1 mL vs. 126.9±74.6 mL, 
p=0.916) did not differ between the nicorandil and control 
groups, respectively. Baseline serum Cr (1.67±0.67 mg/dL 
vs. 1.56±0.45 mg/dL, p=0.173) and cystatin C levels (1.42± 
0.51 mg/L vs. 1.35±0.47 mg/L, p=0.406) were similar be-
tween the nicorandil and control groups. Serum Cr levels at 
Table 2. Procedural and Biochemical Data before and after Coronary Angiography
Nicorandil (n=73) Control (n=76) p value
PCI performed (%) 30 (41.1) 28 (36.8) 0.716
Contrast media
    Volume (mL) 125.6±69.1 126.9±74.6 0.916
    Volume ≥150 mL (%) 20 (27.4) 17 (22.4) 0.603
SCr
    Baseline, mg/dL  1.73±0.60   1.61±0.44 0.166
    At 24 hrs  1.63±0.72   1.55±0.54 0.441
    At 48 hrs  1.68±0.78   1.58±0.56 0.410
    Peak within 48 hrs, mg/dL  1.72±0.78   1.63±0.57 0.469
    Max absolute change, mg/dL -0.01±0.43   0.02±0.31 0.005
    Max relative change, %   -1.58±24.07     0.96±17.49 0.464
Cystatin C
    Baseline, mg/L  1.42±0.51   1.35±0.47 0.406
    At 24 hrs  1.44±0.55   1.40±0.51 0.612
    At 48 hrs  1.45±0.64   1.38±0.48 0.464
    Peak within 48 hrs, mg/L  1.50±0.60   1.45±0.52 0.609
    Max absolute change, mg/L  0.08±0.25   0.09±0.15 0.867
    Max relative change, %    5.57±15.89     6.66±11.21 0.648
PCI, percutaneous coronary intervention; SCr, serum creatinine; Max, maximum.
Fig. 1. Changes in serum creatinine levels. (A) Incidence of contrast-induced nephropathy. (B) Frequency of an increase in serum creatinine level >0.5 mg/dL 
from baseline. (C) Frequency of an increase in serum creatinine level >25% from baseline. CIN, contrast-induced nephropathy; SCr, serum creatinine.
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after adjusting for the influence of variables found to be as-
sociated with CIN in univariate analysis. These included age, 
sex, diabetes mellitus, acute coronary syndrome, baseline 
serum Cr, left ventricular ejection fraction <45%, and mul-
tivessel disease. The analysis showed that prophylactic pre-
treatment with nicorandil did not reduce the risk for CIN 
(Table 3).
Clinical outcomes
No symptoms or hemodynamic changes related to the in-
15.89% vs. 6.66±11.21%, p=0.648) were also similar be-
tween the two groups. The incidences of an increase in se-
rum cystatin C levels >10%, >20%, and 30% from baseline 
were similar between the nicorandil and control groups (Fig. 
2). In subgroups either with baseline eGFR >30 mL/min or 
with eGFR ≤30 mL/min, the incidences of CIN and the in-
crease in serum cystatin C >10% did not differ between the 
nicorandil and control groups (Fig. 3). In the multivariate 
logistic regression analysis, the effect of the pretreatment 
with nicorandil on the development of CIN was evaluated 
Fig. 2. Changes in serum cystatin C levels. Frequency of increases in serum cystatin C >10% (A), >20% (B), and >30% (C) from baseline.
Fig. 3. Incidences of CIN (A and C) and increase in serum cystatin C >10% from baseline (B and D) in patient subgroups with baseline glomerular filtration 
rate (GFR) >30 mL/min (A and B) and ≤30 mL/min (C and D). *p value by Fisher exact test. CIN, contrast-induced nephropathy.
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quirements of the kidney as a whole, and particularly the 
outer medulla.11 Released by endothelial cells, endothelin 
and adenosine are strong vasoconstrictors in the kidney. 
NO and prostaglandin E2 act as potent vasodilators.12,13 One 
study demonstrated that infusion of contrast media marked-
ly decreased blood flow to both the cortex and medulla by 
decreasing activity of NO synthase and by increasing ade-
nosine through hydrolysis of adenosine triphosphate (ATP).13 
Catabolism of adenosine generates ROS that scavenge NO. 
Induced by exposure to contrast media, release of endothe-
lin and prostaglandin from endothelial cells and the in-
crease in adenosine result in decreased blood flow and hy-
poxia in the medulla.7,14
Various preventive measures have been investigated to 
help prevent CIN. Diuretics, mannitol, dopamine, atrial na-
triuretic peptide, endothelin receptor antagonists, fenoldo-
pam, theophylline, ascorbic acid, N-acetylcysteine, and 
statins have all been evaluated in well-designed, prospec-
tive, randomized, double-blinded trials, but either failed to 
show a positive impact on CIN prevention or remained con-
troversial.6,15 A recent study demonstrated that iloprost, an 
analog of prostacyclin, significantly reduced the risk of CIN 
in patients with renal insufficiency undergoing coronary an-
giography or intervention.16 Trimetazidine, an anti-ischemic 
agent, has also shown to be effective in reducing the inci-
dence of CIN in patients with pre-existing renal dysfunc-
tion.17 The efficacy of these agents for the prevention of 
CIN requires further clinical validation. However, these stud-
ies indicate that anti-ischemic drugs may play a beneficial 
role in the prevention of CIN.
Nicorandil, a KATP channel opener and a NO donor, is 
currently used in the treatment of angina and acute heart 
travenous administration of nicorandil were observed dur-
ing and immediately after the intravenous nicorandil infu-
sion. The length of hospital stay after the procedure did not 
differ between the nicorandil and control group, respective-
ly (5.4±5.4 days vs. 4.7±4.4 days, p=0.399). Major adverse 
events occurred in 3 patients (2 cardiac deaths and 1 dialy-
sis) in the nicorandil group and in 2 patients (2 myocardial 
infarctions) in the control group (p=0.974). Acute pulmo-
nary edema was observed in 2 of the 3 patients with major 
adverse events in the nicorandil group and in 1 of the 2 pa-
tients with major adverse events in the control group.
DISCUSSION
This study evaluated whether pretreatment with single intra-
venous dose of nicorandil prevented CIN in patients with re-
nal insufficiency undergoing coronary angiography. Howev-
er, the results failed to identify any preventive pretreatment 
effect of nicorandil on the development of CIN.
Although the exact pathomechanisms of CIN is unknown, 
renal ischemia from an imbalance in vasodilatory and vaso-
constrictive factors, as well as the direct toxic effects of con-
trast media on tubular epithelial cells, are thought to be in-
volved in the development of CIN.6,7 Normally, the majority 
of renal blood flow goes to the cortex, and only 10% is de-
livered to the medulla.7 The deeper portion of the outer me-
dulla is particularly vulnerable to ischemia because the epi-
thelial cells of the thick ascending limb have a relatively 
high oxygen requirement in order to reabsorb salt. The com-
plex interaction of vasodilators and vasoconstrictors modu-
lates renal microcirculation in response to the metabolic re-
Table 3. Impact of the Pretreatment with Nicorandil on the Incidence of Contrast-Induced Nephropathy in a Logistic Regres-
sion Analysis after Adjustment of Covariates
Crude OR Adjusted OR
OR 95% CI p value OR 95% CI p value
Pre-treatment
    Nicrorandil 1.04 0.29-3.77 0.947 0.77 0.16-3.81 0.748
Covariates for adjustment
    Age 0.96 0.90-1.01 0.150 0.95 0.89-1.02 0.151
    Sex 4.17   0.51-33.93 0.182 2.93   0.30-28.87 0.357
    Diabetes mellitus 4.69   0.96-22.87 0.056 4.41   0.68-28.45 0.119
    Baseline SCr 3.34 1.33-8.35 0.010 1.38 0.42-4.56 0.593
    LVEF <45% 4.54   1.04-19.85 0.045 4.06   0.51-32.25 0.185
    ACS 3.85   1.03-14.37 0.045 3.62   0.81-16.10 0.091
    Multivessel disease 3.46   0.86-13.95 0.081 1.69 0.33-8.72 0.529
OR, odds ratio; CI, confidence interval; SCr, serum creatinine; LVEF, left ventricular ejection fraction; ACS, acute coronary syndrome.
All variables found to be associated with contrast-induced nephropathy in univariate analysis with p<0.2 were included as covariates. 
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shown differences between the nicorandil and control groups 
since serum creatinine can peak later than 48 hours after the 
procedure. However, The Acute Kidney Injury Network 
criteria also suggested a period of 48 h for diagnosis to en-
sure that the process being diagnosed is acute and represen-
tative.24 The most common definitions of CIN used in pre-
vious studies were based on the serial measurements of 
serum Cr with 48 hours after contrast exposure.25 A recent 
study reported that measurement of cystatin C at 24 hours 
after administration of contrast agents was efficient for ear-
ly detection of CIN.26 In our study, there were no significant 
changes in serum cystatin C between the two groups. 
In conclusion, this study did not demonstrate a preventive 
effect of single dose intravenous nicorandil on the develop-
ment of CIN in patients undergoing coronary angiography 
or PCI. The role of anti-ischemic agents in the prevention of 
CIN needs to be investigated in further clinical trials.
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